

**National Institutes of Health
National Cancer Institute
Clinical Trials and Translational Research Advisory Committee (CTAC)
NCI Clinical Trials Strategic Planning Subcommittee
Monday, February 25, 2013 — 5:00 p.m. – 6:00 p.m. ET**

CTAC Subcommittee Members

Dr. James L. Abbruzzese (Chair)

Dr. Nancy E. Davidson

Dr. James H. Doroshow (NCI)

Dr. Leslie G. Ford (NCI)

Dr. Scott M. Lippman

Dr. Lori Minasian (NCI)

Ms. Nancy Roach

Dr. Joel Tepper (adhoc)

Dr. Sheila A. Prindiville (NCI, Executive Secretary)

Dr. George Weiner (absent)

Other Attendees

Dr. Monica Bertagnolli

Dr. Kevin Cullen

Dr. Robert Diasio

Dr. Olivera Finn

Ms. Mary McCabe

Dr. Edith Mitchell

Dr. Nikhil Munshi

Dr. Peter Shields

Dr. George Sledge

Dr. Miguel Villalona-Calero

NCI Staff

Ms. Andrea Collins

Ms. Sarah Fabian

Dr. Judy Hautala

Dr. Debbie Jaffe

Dr. LeeAnn Jensen

Ms. Anna Levy

Dr. Meg Mooney

1. Roll Call and Opening Remarks

Dr. James Abbruzzese called to order the conference call of the CTAC National Clinical Trials Strategic Planning Subcommittee and welcomed Subcommittee members, NCI staff and guests. Dr. Abbruzzese read the Opening and Public Statements. He then explained that the purpose of the call was to review the interim report of the NCI Clinical Trials Network (NCTN) Working Group.

2. NCI Clinical Trials Network (NCTN) Working Group Interim Report

Dr. George Sledge, Co-chair of the NCTN Working Group provided the Subcommittee with an update on the progress of the Working Group. The Working Group held its second (of four) meetings in Bethesda, MD, on December 16-17. He reviewed the charge to the WG, which is to assess the strength and balance of the NCTN Program trial portfolio both within and across diseases and recommend new strategic priorities and directions to NCI.

The December meeting refined the process of conducting clinical trials portfolio analysis and developing recommendations by assessing five disease-specific portfolios (breast cancer, gastrointestinal cancer, genitourinary cancer, leukemia and lymphoma.) The Working Group developed interim recommendations to improve clinical cancer research portfolios supported by the NCI. The recommendations will be further refined based on the review of the trial portfolios for the remaining diseases.


3. Wrap-up

Dr. Abbruzzese thanked the Subcommittee members for participating. There being no further business, the conference call was adjourned.



James Abbruzzese, M.D., FACP

Chair of the CTAC



Sheila Prindiville, M.D., M.P.H.

Executive Secretary